MAP1A and prostate adenocarcinoma: PRAD IC gene set does not result significantly enriched for drug actionable targets; yet, it contains 115 hits and 4 of them (ACPP, MAP1A, VKORC1, and VKORC1L1) are targets of drugs used for the PRAD treatment.